Alx Oncology Holdings (ALXO) Return on Capital Employed (2020 - 2026)
Alx Oncology Holdings (ALXO) posted Return on Capital Employed of 92.55% for Q1 2026, up 58.78% sequentially from 224.51% in Q4 2025, and up 2556.0% YoY from 3.48% in Q1 2025.
Alx Oncology Holdings (ALXO) Return on Capital Employed (2020 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Return on Capital Employed for 7 years, with the latest figure at 92.55% in Q1 2026.
- Quarterly Return on Capital Employed rose 2556.0% year-over-year to 92.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92.55% (up 2556.0% YoY) and the FY2025 annual result came in at 131.91%, down 5127.0% from the prior year.
- Return on Capital Employed improved to 92.55% in Q1 2026 per ALXO's latest filing, from 224.51% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 26.38% in Q1 2022 and troughed at 224.51% in Q4 2025.
- A 5-year average of 91.46% and a median of 90.0% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 12841 bps in 2025, then surged 2556 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 44.91% in 2022, then sank by 94 bps to 87.17% in 2023, then slipped by 10 bps to 96.1% in 2024, then sank by 134 bps to 224.51% in 2025, then jumped by 59 bps to 92.55% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 92.55%, 224.51%, and 182.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | -53.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.33% |
| Mar 31, 2026 | -92.55% |
| Dec 31, 2025 | -224.51% |
| Sep 30, 2025 | -182.08% |
| Jun 30, 2025 | -136.28% |
| Mar 31, 2025 | -118.11% |
| Dec 31, 2024 | -96.10% |
| Sep 30, 2024 | -95.26% |
| Jun 30, 2024 | -103.08% |
| Mar 31, 2024 | -90.00% |
| Dec 31, 2023 | -87.17% |
| Sep 30, 2023 | -78.07% |
| Jun 30, 2023 | -56.40% |
| Mar 31, 2023 | -49.88% |
| Dec 31, 2022 | -44.91% |
| Sep 30, 2022 | -40.34% |
| Jun 30, 2022 | -33.72% |
| Mar 31, 2022 | -26.38% |
| Dec 31, 2021 | -22.30% |
| Sep 30, 2021 | -18.32% |